Compare prices and buy BPC-157 + KPV Blend from 4 research peptide vendors - also called suppliers or sources. Updated daily.
A research blend of BPC-157 and KPV. BPC-157 is a synthetic fragment of a protein isolated from human gastric juice, studied in rodent models of gastrointestinal and soft-tissue injury. KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, which suppressed NF-kB inflammatory signaling in cell and mouse colitis studies. No published study has tested the combination, and neither component is FDA-approved.
For research purposes only. Not medical advice.
The BPC-157 and KPV blend combines two research peptides: BPC-157, a 15-residue fragment of a protein isolated from human gastric juice, and KPV, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. As a mixture it has no CAS number of its own, so a certificate of analysis should report each component separately.
Format is what sets this row apart. As of October 2026, every in-stock listing PeptideScouter indexes for the pair is a capsule product, which the site does not price per milligram (the questions below explain why). The vial-total arithmetic the KLOW page sets out for multi-peptide vials does not apply here.
BPC-157's proposed mechanisms, among them nitric oxide signaling and VEGFR2 upregulation, come from cell-culture and rodent injury studies. KPV lacks the core sequence its parent hormone uses to bind melanocortin receptors, and cell and mouse work describes it entering intestinal and immune cells through the PepT1 transporter and suppressing NF-kB signaling. Each component's page carries its evidence and its limits.
The two literatures meet in one place, the inflamed gut. KPV's evidence is chiefly rodent colitis work, and BPC-157's rodent literature includes colitis among its many injury models. Each was tested alone.
A shared disease model is not a shared mechanism. The peptides come from unrelated parent proteins and act on unrelated targets, so the pairing is a market convention rather than a pharmacological one.
A PubMed search on October 21, 2026 for BPC-157 and its spelling variants together with KPV, Lys-Pro-Val or alpha-MSH returned one article, a 2026 review of the FDA compounding advisory committee's peptide recommendations, and no study that tested the two together. A Europe PMC full-text search the same day added two more 2026 papers, neither of which tested the pair. ClinicalTrials.gov returned no record for KPV, alone or combined.
Nor did the literature searches turn up a published rationale for the pairing, on these molecules or on alpha-MSH, the hormone KPV comes from.
Neither component is an FDA-approved drug, and their compounding records have so far run in step. Both were placed in FDA's Category 2, both left it in the same 2026 announcement, and both went before the Pharmacy Compounding Advisory Committee in July 2026. The BPC-157 and KPV pages carry the dates, the votes and FDA's reviews. The arcs had not split by October 21, 2026, when a Federal Register search found no proposed rule naming either. Committee votes are advisory, and the list changes only through notice-and-comment rulemaking. The blend itself was never before the committee, because nominations are made per substance. Our writeup of the July 2026 vote covers all seven substances heard that week.
Neither name carries the two-molecule ambiguity of "TB-500" in Wolverine or the copper question in GHK-Cu + KPV. The open question is salt form. A title reading "BPC-157 + KPV" does not say whether either peptide is the free base or the acetate, the two forms FDA's July 2026 agenda named for each, and vendors describe Pentadeca Arginate, indexed separately, as the BPC-157 sequence supplied as an arginate salt. The KPV page covers a second distinction, free acid versus C-terminal amide. The certificate of analysis is the check.
Two research peptides: BPC-157, a synthetic 15-amino-acid fragment of a protein isolated from human gastric juice, and KPV, the tripeptide Lys-Pro-Val from the C-terminus of alpha-melanocyte-stimulating hormone. The blend has no CAS number of its own because it is a mixture. A certificate of analysis should report each component separately.
PeptideScouter computes a price per milligram only for vials whose contents are stated in milligrams. As of October 2026, every in-stock listing for this blend is a capsule product sold by capsule count, so its listings appear in the price table with their package prices but are left out of every per-milligram median and comparison on the site. A capsule title also does not say whether the amount it states counts a salt form or the free peptide.
No published study of the pair turned up. A PubMed search on October 21, 2026 for BPC-157 together with KPV, Lys-Pro-Val or alpha-MSH and a Europe PMC full-text search the same day found no study that tested the two together, and ClinicalTrials.gov returned no registered trial of KPV, alone or combined. Each peptide has its own preclinical literature, and the pairing is a market convention rather than a pharmacological one.
No. Nominations to the Section 503A bulk drug substances list are made per substance, and no combination product was on the agenda of the Pharmacy Compounding Advisory Committee's July 2026 meeting, where BPC-157 and KPV were each heard separately. Committee votes are advisory, the FDA changes the list only through notice-and-comment rulemaking, and a Federal Register search on October 21, 2026 found no proposed rule naming either. Neither component is an FDA-approved drug.
BPC-157 + KPV Blend is sold by 4 research peptide vendors indexed on PeptideScouter, with 5 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
3 of the 4 indexed vendors currently have BPC-157 + KPV Blend in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 4 vendors listing BPC-157 + KPV Blend publish a PeptideScouter code, worth 10% off. These listings do not carry a comparable per-milligram price, so code availability is shown without a normalized effective price. Each vendor's code is shown beside its price in the table above.
4 research peptide vendors currently list BPC-157 + KPV Blend on PeptideScouter, with 3 in stock right now. We track 5 listings across size and kit variants.
